MGV vs XBI
Vanguard Mega Cap Value ETF vs SPDR S&P Biotech ETF
- • MGV has the lower expense ratio at 0.05% vs 0.35% for XBI.
- • MGV pays a higher dividend yield (1.82%).
Side-by-side metrics
| Metric | MGV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.05% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.82% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $14.39B | $10.92B |
YTD return | 21.01% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.63 | 1.01 |
P/E ratio | 21.02 | — |
Last price | $170.26 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
MGV top holdings
| MU | Micron Technology Inc | 5.91% |
| JPM | JPMorgan Chase & Co | 4.32% |
| BRK-B | Berkshire Hathaway Inc Class B | 3.46% |
| XOM | ExxonMobil Holdings Corp | 3.31% |
| JNJ | Johnson & Johnson | 3.13% |
| ABBV | AbbVie Inc | 2.27% |
| WMT | Walmart Inc | 2.23% |
| COST | Costco Wholesale Corp | 1.98% |
| CVX | Chevron Corp | 1.88% |
| CSCO | Cisco Systems Inc | 1.88% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About MGV
MGV (Vanguard Mega Cap Value ETF) is Mega-cap US value stocks. Managed by Vanguard, the fund carries $14.4B in assets under management, an expense ratio of 0.05%, a dividend yield of 1.82%. Its largest holding is Micron Technology Inc (MU), which represents 5.9% of the portfolio. Real Estate is the fund's largest sector exposure at 1.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.